[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.204.95.166. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
December 1984

Timolol v Guanethidine-Epinephrine Formulations in the Treatment of GlaucomaAn Open Clinical Trial

Author Affiliations

From the Department of Experimental Ophthalmology, The Netherlands Ophthalmic Research Institute, Amsterdam (Drs Hoyng and Verbey); the Glaucoma Department, St Lucas Hospital, Amsterdam (Dr Hoyng); and the Eye Clinic, University of Amsterdam Academic Medical Center (Dr Verbey).

Arch Ophthalmol. 1984;102(12):1788-1793. doi:10.1001/archopht.1984.01040031452021
Abstract

• Patients with glaucoma received either 3% guanethidine-0.5% epinephrine (20 patients) or 1% guanethidine-0.2% epinephrine (20 patients) and then 0.5% timolol maleate. The fall in intraocular pressure during 3% guanethidine-0.5% epinephrine therapy (10.1 mm Hg [34.4%] reduction) was higher than during timolol therapy (7.5 mm Hg [25.5%] reduction) and the response to 1% guanethidine-0.2% epinephrine therapy (7.9 mm Hg [29%] reduction) equaled the response to timolol (7.3 mm Hg [26.8%] reduction). During 3% guanethidine-0.5% epinephrine therapy, 24 (67.7%) of 36 eyes had an average IOP lower than 22 mm Hg, compared with 16 (44.4%) of 36 timolol-treated eyes. With 1% guanethidine-0.2% epinephrine, IOP in 27 (73%) of 37 eyes was less than 22 mm Hg v 23 (62.2%) of 37 timolol-treated eyes. Both guanethidine-epinephrine formulations increased outflow facility. Since timolol produced few side effects, it appears to be the therapy of choice. However, in patients who do not respond sufficiently to timolol, both guanethidine-epinephrine formulations are potent alternatives.

×